Mereo BioPharma Group plc (MREO)

حول

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.